Time to Detectable Metastatic Disease in Patients with Rising Prostate-Specific Antigen Values following Surgery or Radiation Therapy
Open Access
- 15 December 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (24), 8669-8673
- https://doi.org/10.1158/1078-0432.ccr-05-1668
Abstract
Purpose: To determine factors associated with the development of radiographic metastatic progression for patients with recurrent prostate cancer following surgery and/or radiation therapy with prostate-specific antigen (PSA) doubling times of <12 months.Keywords
This publication has 13 references indexed in Scilit:
- Risk of Prostate Cancer–Specific Mortality Following Biochemical Recurrence After Radical ProstatectomyJAMA, 2005
- Outcome Predictors for the Increasing PSA State After Definitive External-Beam Radiotherapy for Prostate CancerJournal of Clinical Oncology, 2005
- PROSTATE SPECIFIC ANTIGEN DOUBLING TIME SUBSEQUENT TO RADICAL PROSTATECTOMY AS A PROGNOSTICATOR OF OUTCOME FOLLOWING SALVAGE RADIOTHERAPYJournal of Urology, 2004
- Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate‐specific antigen level after radical prostatectomy and/or radiation therapyCancer, 2004
- Intermediate End Point for Prostate Cancer-Specific Mortality Following Salvage Hormonal Therapy for Prostate-Specific Antigen FailureJNCI Journal of the National Cancer Institute, 2004
- Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working GroupJournal of Clinical Oncology, 2004
- Surrogate End Point for Prostate Cancer-Specific Mortality After Radical Prostatectomy or Radiation TherapyJNCI Journal of the National Cancer Institute, 2003
- Determinants of Prostate Cancer–Specific Survival After Radiation Therapy for Patients With Clinically Localized Prostate CancerJournal of Clinical Oncology, 2002
- PSA Doubling Time as a Predictor of Clinical Progression After Biochemical Failure Following Radical Prostatectomy for Prostate CancerMayo Clinic Proceedings, 2001
- Natural History of Progression After PSA Elevation Following Radical ProstatectomyJAMA, 1999